Zydus Lifesciences informs about press release

09 Jun 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated June 9, 2023 titled ‘Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in Non-Alcoholic Fatty Liver Disease (NAFLD) patients with comorbidities.’

The above information is a part of company’s filings submitted to BSE.


Zydus Lifesciences Share Price

933.40 -26.15 (-2.73%)
24-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1486.35
Dr. Reddys Lab 5962.50
Cipla 1400.00
Zydus Lifesciences 933.40
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.